Sociedad Americana de Hirudoterapia

Ciprofloxacin-resistant Aeromonas hydrophila cellulitis following leech therapy

Case report published in Journal of Clinical Microbiology (2013)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportSeguridad y control de infeccionesGiltner CL, Bobenchik AM, Uslan DZ, Deville JG, Humphries RM · Journal of clinical microbiology, 2013

Abstract

We report a case of surgical site infection with ciprofloxacin-resistant Aeromonas hydrophila following leech therapy. Antimicrobial and genetic analyses of leech and patient isolates demonstrated that the resistant isolates originated from the leech gut microbiota. These data suggest that ciprofloxacin monotherapy as a prophylaxis regimen prior to leech therapy may not be effective in preventing infection.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article
Indexed MeSH termsAeromonas hydrophilaAnimalsAnti-Bacterial AgentsCellulitisChildCiprofloxacinDrug Resistance, BacterialFemaleGastrointestinal TractGram-Negative Bacterial InfectionsHirudo medicinalisHumans

Resumen

Surgical site cellulitis from ciprofloxacin-resistant Aeromonas hydrophila following leech therapy; antimicrobial and genetic analyses confirmed the resistant strain originated from the leech gut microbiota.

Por qué esto importa para la hirudoterapia

This case report describes a surgical site infection with ciprofloxacin-resistant Aeromonas hydrophila following leech therapy. Antimicrobial and genetic analyses of both leech and patient isolates demonstrated that the resistant isolates originated from the leech gut microbiota. The authors suggest that ciprofloxacin monotherapy as a prophylaxis regimen prior to leech therapy may not be effective in preventing infection. This finding is relevant to hirudotherapy practice, as it provides microbiological and genetic evidence directly linking a drug-resistant pathogen to the leech gut. However, the evidence is limited to a single case report, and no data on the prevalence of ciprofloxacin-resistant A. hydrophila in leech populations or the comparative efficacy of alternative prophylactic regimens are presented.

Citación

Ciprofloxacin-resistant Aeromonas hydrophila cellulitis following leech therapy.

Giltner CL, Bobenchik AM, Uslan DZ, Deville JG, Humphries RM · Journal of clinical microbiology, 2013

DOI

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Safety ProtocolsAeromonas ManagementAeromonasAntimicrobial PeptidesMicrobiome

Añadido a la biblioteca ASH: May 26, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.